The Anxious ResistanceNov 22, 2023
🎥 Exciting news! 🌟 I've just created a video based on a comprehensive guide about Rexulti (Brexpiprazole) that you won't want to miss! 📚🎬 Dive into the details and gain a deeper understanding of this medication. 💊💡 https://youtu.be/0bXwnwcYDEc 📖✨ #Rexulti #Brexpiprazole #VideoGuide #MedicationExplained #MentalHealthMatters
Unveiling the Future of Antipsychotics: The Rise of Brexpiprazole

YouTube
Poetry NewsAug 24, 2023

Agitation
Treat with brexpiprazole
A first antipsychotic
FDA fast-tracks the drug
Dementia response

#dementia #brexpiprazole #antipsychotic #fda #agitation #cinquain #poetry

http://www.medicalnewstoday.com/articles/fda-fast-tracks-brexpiprazole-for-dementia-what-you-need-to-know

FDA fast-tracks antipsychotic drug brexpiprazole for dementia

The FDA fast-tracked brexpiprazole (Rexulti) in May 2023. Rexulti is the first antipsychotic drug to treat agitation for dementia, but there are some risks associated with the drug.

Medical News Today
Show threadWalter StruhalDec 1, 2022
Summary Trial 3 #brexpiprazole 2 or 3mg associated with statist. signif. greater improvement vs. placebo in primary and key secondary efficacy endpoints in #Alzheimers #CTAD22
Walter StruhalDec 1, 2022
#Agitation in Alzheimer’s Dementia: #Brexpiprazole phase III trial- George Grossberg #CTAD22
previous trials https://www.sciencedirect.com/science/article/pii/S1064748119305214
Trial 3: use of 2mg and 3mg
- Design: randomized 2:1 2mg oder 3mg vs. Placebo
- Results: 2 or 3mg significant improvement
- Safety: AE - similar rates than placebo, sedation, extrapyramidal disorders, falls - only few reported on that, 3mg higher rate on discontinuation - no consistant pattern pattern in this group